Article
Multidisciplinary Sciences
Lakshini Yasaswi Herat, Jennifer Rose Matthews, Moira Hibbs, Elizabeth Piroska Rakoczy, Markus Peter Schlaich, Vance Bruce Matthews
Summary: SGLTs are transport proteins that can be inhibited to improve glycemic control and provide cardiorenal benefits. Dual SGLT1/2 inhibitors, such as sotagliflozin, target both SGLT1 and 2 proteins.
Article
Multidisciplinary Sciences
Worapaka Manosroi, Pojsakorn Danpanichkul, Pichitchai Atthakomol
Summary: This meta-analysis demonstrates that the use of SGLT2 inhibitors in type 2 diabetes patients does not significantly affect plasma aldosterone concentration, but leads to significantly higher plasma renin activity levels, especially in short-term use.
SCIENTIFIC REPORTS
(2022)
Article
Endocrinology & Metabolism
Ikuro Matsuba, Masahiro Takihata, Masahiko Takai, Hajime Maeda, Akira Kubota, Kotaro Iemitsu, Shinichi Umezawa, Mitsuo Obana, Mizuki Kaneshiro, Takehiro Kawata, Tetsuo Takuma, Hiroshi Takeda, Hideo Machimura, Atsuko Mokubo, Tetsuya Motomiya, Taro Asakura, Taisuke Kikuchi, Yoko Matsuzawa, Shogo Ito, Masaaki Miyakawa, Yasuo Terauchi, Akira Kanamori
Summary: In a study involving 107 patients with type 2 diabetes treated with canagliflozin for 12 months, significant decreases in body weight, body fat, and mineral mass were observed. Total body water was not affected, suggesting that SGLT2 inhibitors may reduce body weight by regulating fat mass or water distribution.
DIABETES OBESITY & METABOLISM
(2021)
Article
Endocrinology & Metabolism
Mariam Alatrach, Christina Agyin, Carolina Solis-Herrera, Olga Lavryneko, John Adams, Amalia Gastaldelli, Curtis Triplitt, Ralph A. DeFronzo, Eugenio Cersosimo
Summary: This study found that SGLT2 inhibitors have an effect on the increase of endogenous glucose production (EGP) in patients with type 2 diabetes after oral glucose intake. Despite elevated plasma insulin and glucagon, the stimulation of EGP was observed, suggesting that additional factors may be involved.
Article
Pharmacology & Pharmacy
Lili He, Sai Ma, Qingjuan Zuo, Guorui Zhang, Zhongli Wang, Tingting Zhang, Jianlong Zhai, Yifang Guo
Summary: This study investigated the protective effect of canagliflozin on myocardial metabolism and heart under stress overload. Canagliflozin showed improvement in cardiac hypertrophy, fibrosis, and left ventricular diastolic dysfunction induced by hypertension. The activation of the AMPK/SIRT1/PGC-1α pathway by canagliflozin was suggested to regulate energy metabolism and oxidative stress.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Pharmacology & Pharmacy
Sjoukje van Der Hoek, Antoon T. M. Willemsen, Ton Visser, Andre Heeres, Douwe J. Mulder, Reinoud P. H. Bokkers, Riemer H. J. A. Slart, Philip H. Elsinga, Hiddo J. L. Heerspink, Jasper Stevens
Summary: SGLT2 inhibitors reduce cardiovascular and kidney risks, but there is individual variation in response. The use of [F-18]canagliflozin PET imaging in this study helped determine the association between clinical canagliflozin doses and SGLT2 occupancy.
CLINICAL PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Physiology
Ting Wang, Jianmin Li, Hui Li, Xin Zhong, Luya Wang, Shujue Zhao, Xuesheng Liu, Zhouqing Huang, Yonghua Wang
Summary: The study found that aerobic exercise can reverse cardiac remodeling in diabetic mice by inhibiting the expression of P2X7R in cardiomyocytes, including changes in fibrosis and apoptosis.
FRONTIERS IN PHYSIOLOGY
(2022)
Article
Medicine, Research & Experimental
Hong Wang, Minyi Huang, Weijian Bei, Yiqi Yang, Lixia Song, Dongxing Zhang, Wenjing Zhan, Yuzhen Zhang, Xu Chen, Weixuan Wang, Lexun Wang, Jiao Guo
Summary: FTZ can attenuate NASH by ameliorating steatosis and hepatocyte apoptosis through regulating the AMPK pathway.
BIOMEDICINE & PHARMACOTHERAPY
(2021)
Article
Endocrinology & Metabolism
SokCin Tye, Megumi Oshima, Clare Arnott, Brendon L. Neuen, Robert A. Fletcher, Bruce Neal, Hiddo J. L. Heerspink
Summary: This study aimed to investigate the association between improvements in multiple cardiovascular risk markers and the risk of cardiovascular and kidney outcomes in patients with type 2 diabetes and high cardiovascular risk participating in the CANVAS program. The results showed that improvements in multiple risk markers were associated with a reduced risk of cardiovascular and kidney outcomes.
DIABETES OBESITY & METABOLISM
(2023)
Article
Endocrinology & Metabolism
Kent Y. Feng, JingWei Li, Juliana Ianus, Dick de Zeeuw, Greg R. Fulcher, Michael Pfeifer, David R. Matthews, Meg J. Jardine, Vlado Perkovic, Bruce Neal, Kenneth W. Mahaffey
Summary: In the CANVAS program, the most common reasons for hospitalization were cardiac disorders, infections and infestations, and nervous system disorders. Canagliflozin, compared with placebo, reduced the rate of total ACH.
DIABETES OBESITY & METABOLISM
(2021)
Article
Endocrinology & Metabolism
Limin Wang, Chenghong Liang, Xiaojian Song, Xiaoyan Jia, Xiudan Wang, Yun Zhang, Qinyuan Xie, Nan Zheng, Huijuan Yuan
Summary: This study aimed to assess alterations in the gut, oral, and ocular surface microbiota pre- and post-Cana treatment in patients with type 2 diabetes mellitus (T2DM). The results showed that there were significant changes in the gut, oral, and ocular surface microbiota after Cana treatment, which were related to changes in clinical parameters.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Article
Endocrinology & Metabolism
Hiddo J. L. Heerspink, Ellen Apperloo, Melanie Davies, Dror Dicker, Kristian Kandler, Julio Rosenstock, Rasmus Sorrig, Jack Lawson, Niels Zeuthen, David Cherney
Summary: These post hoc analyses explored the effects of semaglutide on kidney function in people with obesity. The results showed that semaglutide improved UACR in overweight/obese individuals with type 2 diabetes, but did not have an effect on eGFR decline in those with normal kidney function.
Article
Endocrinology & Metabolism
Dario Giugliano, Miriam Longo, Paola Caruso, Maria Ida Maiorino, Giuseppe Bellastella, Katherine Esposito
Summary: This meta-analysis evaluates the cardiorenal outcomes of SGLT-2is in patients with type 2 diabetes, finding that SGLT-2is are associated with a reduced risk of major adverse cardiovascular events and significant benefits in the progression of diabetic kidney disease. There was no significant heterogeneity observed based on the presence or absence of cardiovascular disease in patients.
DIABETES OBESITY & METABOLISM
(2021)
Review
Endocrinology & Metabolism
Nicole Kattner
Summary: The different types of diabetes have varying disease pathogenesis, but all result in the impairment or loss of & beta;-cell function, leading to chronic hyperglycemia. In diabetes, immune cells are increased in number and activation, with different patterns and compositions of inflammation observed. Immune cells, pancreatic stellate cells, and fibrosis contribute to & beta;-cell dysfunction and the development and progression of diabetes. Initial studies on anti-inflammatory drugs show their ability to rescue & beta;-cell function and their potential benefits in diabetes treatment.
THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM
(2023)
Article
Endocrinology & Metabolism
Evangelos K. Oikonomou, Marc A. Suchard, Darren K. McGuire, Rohan Khera
Summary: This study developed a machine learning-based decision support tool to personalize the assessment of canagliflozin treatment benefits for ASCVD in patients with type 2 diabetes. The tool was validated in two trials, CANVAS and CANVAS-R, and was able to identify patient phenotypes with greater ASCVD canagliflozin effects.
Article
Pharmacology & Pharmacy
Mary Priyanka Udumula, Brahmam Medapi, Indu Dhar, Audesh Bhat, Kaushik Desai, Dharmarajan Sriram, Arti Dhar
Article
Pharmacology & Pharmacy
Jaspreet Kalra, Suresh Babu Mangali, Audesh Bhat, Indu Dhar, Mary Priyanka Udumula, Arti Dhar
FUNDAMENTAL & CLINICAL PHARMACOLOGY
(2018)
Article
Biochemistry & Molecular Biology
Sureshbabu Mangali, Audesh Bhat, Mary Priyanka Udumula, Indu Dhar, Dharmarajan Sriram, Arti Dhar
JOURNAL OF CELLULAR BIOCHEMISTRY
(2019)
Article
Medicine, Research & Experimental
Mary Priyanka Udumula, Audesh Bhat, Sureshbabu Mangali, Jaspreet Kalra, Indu Dhar, Dharamrajan Sriram, Arti Dhar
Review
Pharmacology & Pharmacy
Jaspreet Kalra, Suresh Babu Mangali, Deepika Dasari, Audesh Bhat, Srashti Goyal, Indu Dhar, Dharamrajan Sriram, Arti Dhar
FUNDAMENTAL & CLINICAL PHARMACOLOGY
(2020)
Article
Pharmacology & Pharmacy
Sureshbabu Mangali, Audesh Bhat, Deepika Dasari, Dharmarajan Sriram, Arti Dhar
Summary: Protein kinase R (PKR) inhibition attenuated myocardial dysfunction, cardiac fibrosis, oxidative/nitrosative stress, inflammation, cell death, and interrelated signalling pathways in a myocardial ischemia model. Inhibition of PKR improved ischemia-mediated inflammation, apoptosis, cardiac hypertrophy, and fibrosis, suggesting it as a potential intervention therapy for myocardial ischemia.
EUROPEAN JOURNAL OF PHARMACOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Trupti Ghatage, Sameer Singh, Kalyaneswar Mandal, Arti Dhar
Summary: The study aimed to determine the effect of co-activation of MasR and pGCA pathways by synthesized novel peptide (NP) on oxidative stress-induced VSMCs and ECs. Results showed that NP significantly improved oxidative stress-induced injury in VSMCs, and its action was superior to Ang1-7 and BNP. Mechanistic study suggested the involvement of calcium inhibition for the therapeutic effect of NP on EC-dependent VSMC relaxation. NP may represent a promising strategy for CVDs.
JOURNAL OF CELLULAR BIOCHEMISTRY
(2023)
Article
Biochemistry & Molecular Biology
Ganesh Panditrao Lahane, Arti Dhar
Summary: This study explored the role of Nesfatin-1 in renal epithelial cells under chronic oxidative stress-induced conditions. The results showed that Nesfatin-1 expression was decreased in cells induced with high glucose and H2O2. Moreover, co-treatment with Nesfatin-1 attenuated the effects of oxidative stress, apoptosis, and fibrosis.
Article
Chemistry, Medicinal
Deepika Dasari, Audesh Bhat, Sureshbabu Mangali, Trupti Ghatage, Ganesh Panditrao Lahane, Dharmarajan Sriram, Arti Dhar
Summary: This study examines the effects of sodium-dependent glucose cotransporter 2 inhibitors (SGLT2) on cardiomyocytes under glucolipotoxic conditions. The results suggest that inhibiting SGLT2 can attenuate the harmful effects of high glucose and high lipid on cardiomyocytes, indicating that inhibiting SGLT2 may be a possible approach for treating cardiovascular disease in diabetic patients.
ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE
(2022)
Article
Multidisciplinary Sciences
Jaspreet Kalra, Audesh Bhat, KirtiKumar B. Jadhav, Arti Dhar